Aller au contenu principal
xMedica

NCT07321899ClinicalTrials.gov

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Interventionnelle1 186 participants recherchés20 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-07; recorded start 2026-09-11
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Cardiovascular)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 4 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,186 participants (target), run at 20 sites.

How this score is built
  • Enrolment31/40

    1,186 participants (target)

  • Site count7/25

    4 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 179 months

  • Sponsor scale4/10

    Medtronic Cardiovascular has led 19 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Prospective, global, pre-market, interventional, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation.

Affections

  • Severe Tricuspid Regurgitation

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Age ≥18 years at the time of consent. * Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT). * Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR. Exclusion Criteria: * Any tricuspid device currently in place. * Anatomic contraindications. * Need for emergent or urgent surgery. * Left ventricular ejection fraction \<25%.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhaseSans objet
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuSINGLE (1)
Recrutement1 186 participants recherchés

Promoteur et collaborateurs

  • Medtronic Cardiovascular Promoteur

Groupes et interventions

  • Medtronic Intrepid™ TTVREXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation.

  • Edwards EVOQUE TTVRACTIVE_COMPARATOR

    Transcatheter tricuspid valve replacement with Edwards EVOQUE TTVR in patients with severe or greater tricuspid regurgitation.

  • Single Arm RegistryEXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation who are not eligible for randomization.

Interventions

  • Dispositif Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

  • Dispositif Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

Critères de jugement

  1. Critère de jugement principal

    Rate of Major Adverse Events (MAE)

    Délai 30-days post-procedure

  2. Critère de jugement principal

    Composite Endpoint: All-cause mortality, Heart failure hospitalization, and tricuspid valve reintervention

    Délai 1-year post-procedure

  3. Critère de jugement secondaire

    Tricuspid regurgitation (TR) grade reduction

    Total number of patients with at least one grade TR reduction

    Délai 6 months post-procedure

  4. Critère de jugement secondaire

    Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline

    KCCQ overall summary score is a patient-reported measure of health status. Scores range from 0 to 100 where higher scores reflect better quality of life

    Délai 6 months post-procedure

  5. Critère de jugement secondaire

    All-cause mortality

    Délai 12 months post-procedure

  6. Critère de jugement secondaire

    Heart failure hospitalization

    Délai 12 months post-procedure

  7. Critère de jugement secondaire

    New onset conduction disturbance (NOCD)

    Délai 30 days post-procedure

  8. Critère de jugement secondaire

    Total procedure time

    Délai Procedure

  9. Critère de jugement secondaire

    Right ventricle (RV) dysfunction

    Délai 12 months post-procedure

Dates

Dates
Date de début11 septembre 2026 (réelle)
Achèvement principal1 septembre 2031 (estimée)
Achèvement1 avril 2041 (estimée)
Première publication7 janvier 2026 (réelle)
Dernière mise à jour12 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisnovembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

20 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Emory University Hospital MidtownAtlantaGeorgiaEn recrutement
University of Alabama at Birmingham (UAB) HospitalBirminghamAlabamaEn recrutement
Buffalo General Medical CenterBuffaloNew YorkEn recrutement
Northwestern Memorial HospitalChicagoIllinoisEn recrutement
The Christ HospitalCincinnatiOhioEn recrutement
Cleveland Clinic FoundationClevelandOhioEn recrutement
Hartford HospitalHartfordConnecticutEn recrutement
Cedars Sinai Medical CenterLos AngelesCaliforniaEn recrutement
Northwell Health North Shore University HospitalManhassetNew YorkEn recrutement
Abbott Northwestern HospitalMinneapolisMinnesotaEn recrutement
Morristown Medical CenterMorristownNew JerseyEn recrutement
Yale New Haven HospitalNew HavenConnecticutEn recrutement
Montefiore Medical CenterNew YorkNew YorkEn recrutement
NYU Langone Medical CenterNew YorkNew YorkEn recrutement
The Valley HospitalParamusNew JerseyEn recrutement
Abrazo Arizona Heart HospitalPhoenixArizonaEn recrutement
Kaiser Permanente San Francisco Medical CenterSan FranciscoCaliforniaEn recrutement
Los Robles Hospital & Medical CenterThousand OaksCaliforniaEn recrutement
Ascension Via Christi Saint FrancisWichitaKansasEn recrutement
Lankenau Institute for Medical ResearchWynnewoodPennsylvaniaEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 12 novembre 2026

    Site ajouté

    7 sites added (20 total)

    1320

  2. 25 septembre 2026

    Site ajouté

    9 sites added (13 total)

    413

  3. 28 juillet 2026

    Statut modifié

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 28 juillet 2026

    Recrutement ouvert

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 28 juillet 2026

    Site ajouté

    4 sites added (4 total)

    04